WhaleCreep

Casdin Capital, LLC 13F holdings, Q1 2022

Hedge fundSEC filingsCompare with another fundHoldings as of 2022-03-31, filed 2022-05-16

Casdin Capital, LLC disclosed 47 US equity positions worth $2.2bn in its Q1 2022 13F filing. Its largest position is BLFS at 7.7% of the reported book, followed by ALNY and EQRX INC. Versus Q4 2021 it opened 2 new positions, added to 1, reduced 7 and exited 8.

$2.2bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
47
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
7.7%
Largest position
The largest single position as a share of the reported equity book.
55.2%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
24
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
43
Quarters on file since Q4 2015
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q4 2021: 2 new, 1 added, 7 reduced, 8 exited

47 rows
BLFS BIOLIFE SOLUTIONS INCHealthcare7.7%$172m7.57m0.0%held
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare7.3%$163m1.00m0.0%held
EQRX INC no ticker–7.3%$163m39.53m0.0%held
FATE FATE THERAPEUTICS INCHealthcare5.9%$132m3.40m0.0%held
RLAY RELAY THERAPEUTICS INCHealthcare5.2%$115m3.86m0.0%held
SLGCUSD SOMALOGIC INC–4.5%$99.4m12.39m0.0%held
2655787D BLUEPRINT MEDICINES CORP–4.4%$99.0m1.55m0.0%held
MXCT MAXCYTE INCHealthcare4.4%$97.7m13.97m0.0%held
NVTA1EUR INVITAE CORP–4.4%$97.3m12.20m0.0%held
EXK EXACT SCIENCES CORPBasic Materials4.2%$93.0m1.33m−35%reduced
PACB PACIFIC BIOSCIENCES CALIF INHealthcare3.3%$72.7m7.99m0.0%held
VERVE THERAPEUTICS INC no ticker–3.2%$71.6m3.14m0.0%held
ABSI ABSCI CORPORATIONHealthcare2.9%$65.1m7.72m0.0%held
SRPT SAREPTA THERAPEUTICS INCHealthcare2.8%$62.5m800,000−41%reduced
AGIO AGIOS PHARMACEUTICALS INCHealthcare2.7%$60.8m2.09m0.0%held
RVMD REVOLUTION MEDICINES INCHealthcare2.7%$60.5m2.37m0.0%held
DNLI DENALI THERAPEUTICS INCHealthcare2.2%$48.3m1.50m0.0%held
BEAM BEAM THERAPEUTICS INCHealthcare2.1%$46.9m818,8200.0%held
GBTUSD GLOBAL BLOOD THERAPEUTICS IN–2.1%$45.9m1.32m0.0%held
TWST TWIST BIOSCIENCE CORPHealthcare1.9%$43.5m880,000+31%added
CDNA CAREDX INCHealthcare1.9%$42.7m1.15m0.0%held
TNYA TENAYA THERAPEUTICS INCHealthcare1.9%$42.3m3.59m0.0%held
TNGX TANGO THERAPEUTICS INCHealthcare1.9%$41.6m5.49m0.0%held
IPSC CENTURY THERAPEUTICS INCHealthcare1.8%$40.4m3.21m0.0%held
ONC BEIGENE LTDHealthcare1.3%$28.3m150,0000.0%held
GH GUARDANT HEALTH INCHealthcare1.2%$27.8m420,000−47%reduced
DMTKQ DERMTECH INC–1.1%$25.6m1.75m0.0%held
GINKGO BIOWORKS HOLDINGS INC no ticker–0.8%$16.9m4.20m−2.9%reduced
WGS GENEDX HOLDINGS CORPHealthcare0.7%$15.3m5.00m0.0%held
ADPT ADAPTIVE BIOTECHNOLOGIES CORHealthcare0.6%$13.9m1.00m0.0%held
GLUE MONTE ROSA THERAPEUTICS INCHealthcare0.6%$13.5m960,8820.0%held
SEER SEER INCHealthcare0.5%$12.2m800,0000.0%held
TSVT* 2SEVENTY BIO INC–0.5%$10.5m614,754–new
EXAIEUR EXSCIENTIA PLC–0.5%$10.3m713,9000.0%held
GBIOGBX GENERATION BIO CO–0.4%$9.7m1.32m0.0%held
SCIENCE 37 HOLDINGS INC no ticker–0.4%$9.6m1.80m0.0%held
SINGULAR GENOMICS SYSTEMS IN no ticker–0.4%$9.1m1.44m0.0%held
MRTXEUR MIRATI THERAPEUTICS INC–0.4%$8.4m102,500–new
FDMT 4D MOLECULAR THERAPEUTICS INHealthcare0.4%$8.4m555,4550.0%held
MAGENTA THERAPEUTICS INC no ticker–0.4%$8.0m2.77m−29%reduced
ZLAB ZAI LAB LTDHealthcare0.3%$6.6m150,0000.0%held
CDXS CODEXIS INCHealthcare0.3%$6.2m300,000−93%reduced
KRON1USD KRONOS BIO INC–0.2%$4.2m583,4360.0%held
RXRX RECURSION PHARMACEUTICALS INHealthcare0.2%$3.9m548,1560.0%held
ORIC ORIC PHARMACEUTICALS INCHealthcare0.1%$3.2m601,5150.0%held
DECIBEL THERAPEUTICS INC no ticker–0.04%$1.0m330,000−72%reduced
LIANY LIANBIO–0.03%$766k206,4150.0%held

Exited since Q4 2021

8 rows
ALLO ALLOGENE THERAPEUTICS INC1.1%$39.5m
ALEC ALECTOR INC1.0%$34.1m
CRSP CRISPR THERAPEUTICS AG0.6%$20.2m
23ANDME HOLDING CO no ticker0.3%$12.3m
MASS 908 DEVICES INC0.3%$10.5m
BLIUSD PHENOMEX INC0.1%$3.6m
STOK STOKE THERAPEUTICS INC0.08%$2.9m
SANA SANA BIOTECHNOLOGY INC0.03%$929k

Sector mix

  • Healthcare64.9%
  • Unclassified31.0%
  • Basic Materials4.2%

Book over time

Every quarter on file (43)
QuarterPositionsEquity book
Q2 202643$2.0bn
Q1 202640$1.3bn
Q4 202538$1.6bn
Q3 202532$1.2bn
Q2 202533$1.1bn
Q1 202544$1.2bn
Q4 202438$1.5bn
Q3 202435$1.5bn
Q2 202438$1.3bn
Q1 202436$1.3bn
Q4 202336$1.0bn
Q3 202338$897m
Q2 202341$1.1bn
Q1 202340$1.2bn
Q4 202244$1.3bn
Q3 202236$1.5bn
Q2 202240$1.2bn
Q1 202247$2.2bn
Q4 202153$3.5bn
Q3 202153$4.0bn
Q2 202154$3.9bn
Q1 202148$3.4bn
Q4 202050$3.4bn
Q3 202045$2.2bn
Q2 202042$1.7bn
Q1 202038$942m
Q4 201931$1.1bn
Q3 201933$966m
Q2 201931$1.1bn
Q1 201929$910m
Q4 201831$585m
Q3 201834$814m
Q2 201832$709m
Q1 201830$565m
Q4 201726$409m
Q3 201726$354m
Q2 201731$250m
Q1 201729$170m
Q4 201625$121m
Q3 201626$123m
Q2 201624$95.7m
Q1 201625$84.5m
Q4 201527$107m

Where Casdin Capital, LLC was early

41 rows
EDIT EDITAS MEDICINE INCQ1 20162 of 963.5%3.5%15Held at last filing, Q2 2026−91%
ONC BEIGENE LTDQ1 20169 of 1041.1%2.1%16Exited by Q2 2025+829%
EVH EVOLENT HEALTH INCQ2 20161 of 1304.8%7.7%12Exited by Q2 2019−34%
T8S TESARO INCQ2 20168 of 831.8%2.7%4Exited by Q4 2017+54%
MDRX ALLSCRIPTS HEALTHCARE SOLUTNQ3 20168 of 962.1%2.4%3Exited by Q2 2017−3.7%
CDXS CODEXIS INCQ1 20172 of 801.9%8.1%29Exited by Q3 2025−49%
PACB PACIFIC BIOSCIENCES CALIF INQ1 20173 of 1182.1%5.1%21Held at last filing, Q2 2026−68%
SGMOQ SANGAMO THERAPEUTICS INCQ1 20173 of 852.6%5.9%19Exited by Q3 2022−20%
FATE FATE THERAPEUTICS INCQ2 20174 of 1070.7%8.3%27Exited by Q1 2024+15%
CRSP CRISPR THERAPEUTICS AGQ1 20181 of 1201.1%1.8%11Exited by Q1 2022+66%
ZLAB ZAI LAB LTDQ1 20186 of 990.5%1.0%11Exited by Q2 2022+106%
BLFS BIOLIFE SOLUTIONS INCQ2 20181 of 781.6%16.3%33Held at last filing, Q2 2026+148%
CDNA CAREDX INCQ2 20186 of 1030.3%3.0%16Exited by Q2 2022+202%
CNST CONSTELLATION PHARMCETICLS IQ3 20181 of 721.1%5.3%12Exited by Q3 2021–
2JQ GRITSTONE ONCOLOGY INCQ3 20182 of 621.3%1.9%8Exited by Q3 2020−53%
SRPT SAREPTA THERAPEUTICS INCQ3 201814 of 1820.8%13.7%29Held at last filing, Q2 2026−89%
DNLI DENALI THERAPEUTICS INCQ4 20182 of 1040.4%3.7%31Held at last filing, Q2 2026+24%
ALEC ALECTOR INCQ1 20194 of 870.7%2.8%12Exited by Q1 2022+10%
TWST TWIST BIOSCIENCE CORPQ2 20192 of 990.8%4.2%17Exited by Q3 2023−29%
ADPT ADAPTIVE BIOTECHNOLOGIES CORQ2 20194 of 1301.9%2.3%12Exited by Q2 2022−71%
FULC FULCRUM THERAPEUTICS INCQ3 20191 of 950.6%1.9%8Exited by Q3 2021+58%
RVMD REVOLUTION MEDICINES INCQ1 20201 of 1643.1%24.2%26Held at last filing, Q2 2026+755%
DMTKQ DERMTECH INCQ1 20202 of 470.6%2.6%9Exited by Q2 2022+31%
ALLO ALLOGENE THERAPEUTICS INCQ1 20204 of 941.0%1.6%8Exited by Q1 2022−23%
GBIOGBX GENERATION BIO COQ2 20201 of 482.0%2.2%8Exited by Q2 2022−65%
RLAY RELAY THERAPEUTICS INCQ3 20201 of 1117.3%15.0%24Held at last filing, Q2 2026−56%
FDMT 4D MOLECULAR THERAPEUTICS INQ4 20201 of 941.0%2.1%16Exited by Q1 2025−87%
BEAM BEAM THERAPEUTICS INCQ4 20203 of 981.1%3.2%23Held at last filing, Q2 2026−58%
ABCL ABCELLERA BIOLOGICS INCQ4 20207 of 870.2%1.8%9Exited by Q2 2024−89%
IPSC CENTURY THERAPEUTICS INCQ2 20213 of 512.4%2.4%21Held at last filing, Q2 2026−92%
TNYA TENAYA THERAPEUTICS INCQ3 20211 of 531.8%3.3%20Held at last filing, Q2 2026−96%
ABSI ABSCI CORPORATIONQ3 20212 of 762.2%2.9%20Held at last filing, Q2 2026−0.3%
MXCT MAXCYTE INCQ3 20212 of 634.3%5.6%9Exited by Q4 2023−74%
TNGX TANGO THERAPEUTICS INCQ3 20212 of 1031.8%1.9%13Exited by Q2 2025−89%
WGS GENEDX HOLDINGS CORPQ3 20215 of 1040.9%29.5%20Held at last filing, Q2 2026−73%
TSVT* 2SEVENTY BIO INCQ1 20224 of 700.5%1.8%13Exited by Q2 2025−71%
PLRX PLIANT THERAPEUTICS INCQ3 20228 of 1031.0%3.7%8Exited by Q3 2024−49%
PRME PRIME MEDICINE INCQ4 20223 of 621.1%1.5%15Held at last filing, Q2 2026−80%
GPCR STRUCTURE THERAPEUTICS INCQ1 20231 of 1141.3%6.9%14Held at last filing, Q2 2026+126%
NGNE NEUROGENE INCQ4 20232 of 451.0%2.4%11Held at last filing, Q2 2026+62%
MAZE MAZE THERAPEUTICS INCQ1 20259 of 820.9%2.0%6Held at last filing, Q2 2026+171%

Concentration and tenure

12.9%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
65.0%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters